CN102439452B - 通过测量her-2表达确定患者应答的方法 - Google Patents

通过测量her-2表达确定患者应答的方法 Download PDF

Info

Publication number
CN102439452B
CN102439452B CN201080009544.4A CN201080009544A CN102439452B CN 102439452 B CN102439452 B CN 102439452B CN 201080009544 A CN201080009544 A CN 201080009544A CN 102439452 B CN102439452 B CN 102439452B
Authority
CN
China
Prior art keywords
amount
homodimer
threshold level
purposes
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080009544.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102439452A (zh
Inventor
M·贝茨
J·W·库克
G·迪德里希
L·古德曼
A·慕克吉
G·帕里
J·斯珀林德
S·J·威廉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labcorp Holdings Inc
Original Assignee
Laboratory Corp of America Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42340111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102439452(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratory Corp of America Holdings filed Critical Laboratory Corp of America Holdings
Publication of CN102439452A publication Critical patent/CN102439452A/zh
Application granted granted Critical
Publication of CN102439452B publication Critical patent/CN102439452B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201080009544.4A 2009-01-15 2010-01-15 通过测量her-2表达确定患者应答的方法 Expired - Fee Related CN102439452B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14502909P 2009-01-15 2009-01-15
US61/145,029 2009-01-15
PCT/US2010/021272 WO2010083463A1 (en) 2009-01-15 2010-01-15 Methods of determining patient response by measurement of her-2 expression

Publications (2)

Publication Number Publication Date
CN102439452A CN102439452A (zh) 2012-05-02
CN102439452B true CN102439452B (zh) 2015-04-15

Family

ID=42340111

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080009544.4A Expired - Fee Related CN102439452B (zh) 2009-01-15 2010-01-15 通过测量her-2表达确定患者应答的方法

Country Status (12)

Country Link
US (3) US20100233732A1 (enExample)
EP (1) EP2387717B1 (enExample)
JP (2) JP2012515353A (enExample)
KR (1) KR20110120890A (enExample)
CN (1) CN102439452B (enExample)
AU (1) AU2010204576A1 (enExample)
BR (1) BRPI1007048A2 (enExample)
CA (1) CA2749817A1 (enExample)
ES (1) ES2526519T3 (enExample)
IL (1) IL214067A0 (enExample)
SG (1) SG172984A1 (enExample)
WO (1) WO2010083463A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
WO2009070772A1 (en) 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
ES2637411T3 (es) 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
US11401344B2 (en) 2008-12-01 2022-08-02 Laboratory Corporation Of America Holdings Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
ES2535723T3 (es) 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente mediante la medición de Her-3
WO2012015765A2 (en) 2010-07-27 2012-02-02 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
ES2701929T3 (es) 2011-05-19 2019-02-26 Laboratory Corp America Holdings Métodos para determinar la probabilidad de supervivencia y para predecir la probabilidad de metástasis en el cáncer
FR2993668B1 (fr) * 2012-07-17 2015-07-03 Cisbio Bioassays Methode theranostique basee sur la detection de dimeres her2-her2
WO2014165855A1 (en) 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
WO2016083364A1 (en) * 2014-11-25 2016-06-02 Ventana Medical Systems, Inc. Proximity assays using chemical ligation and hapten transfer
WO2017014694A1 (en) * 2015-07-23 2017-01-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment
JP2019515252A (ja) 2016-03-15 2019-06-06 ラボラトリー コーポレイション オブ アメリカ ホールディングス 細胞間のタンパク質相互作用を評価する方法
PL3519437T3 (pl) 2016-09-30 2022-01-17 F. Hoffmann-La Roche Ag Przeciwciała dwuswoiste przeciwko p95HER2
JP6922444B2 (ja) * 2016-11-11 2021-08-18 コニカミノルタ株式会社 蛍光ナノ粒子を用いた、病理学的完全奏効（ｐＣＲ）の予測を支援するための検査支援方法
WO2019241599A1 (en) * 2018-06-14 2019-12-19 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
KR102317202B1 (ko) * 2018-10-19 2021-10-25 주식회사 프로티나 유방암 재발 예측 방법
KR20230134232A (ko) 2022-03-14 2023-09-21 부산대학교 산학협력단 백금계 항암제에 대한 난소암 환자의 약물 반응성 예측용 다중 바이오마커 조성물 및 이를 이용한 진단방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1928563A (zh) * 2005-09-09 2007-03-14 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
EP1918386A9 (en) * 2002-03-13 2008-07-09 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
CN101230390A (zh) * 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026403A1 (en) * 1994-03-29 1995-10-05 Celltech Therapeutics Limited Antibodies against e-selectin
SE9601676D0 (sv) * 1996-04-30 1996-04-30 Ulf Landegren Improved probing of specific mucleic acids
US6335479B1 (en) * 1998-10-13 2002-01-01 Dai Nippon Printing Co., Ltd. Protective sheet for solar battery module, method of fabricating the same and solar battery module
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6682887B1 (en) * 1999-04-30 2004-01-27 Aclara Biosciences, Inc. Detection using degradation of a tagged sequence
US20040248150A1 (en) * 1999-04-02 2004-12-09 Sharat Singh Methods employing oligonucleotide-binding e-tag probes
US6322980B1 (en) * 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US20030235832A1 (en) * 2000-06-21 2003-12-25 Ahmed Chenna Multiplexed analysis by chromatographic separation of molecular tags
US6673550B2 (en) * 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US7001725B2 (en) * 1999-04-30 2006-02-21 Aclara Biosciences, Inc. Kits employing generalized target-binding e-tag probes
US7037654B2 (en) * 1999-04-30 2006-05-02 Aclara Biosciences, Inc. Methods and compositions for enhancing detection in determinations employing cleavable electrophoretic tag reagents
US20030092012A1 (en) * 2001-11-09 2003-05-15 Ahmed Chenna Methods for detecting a plurality of analytes by chromatography
US6649351B2 (en) * 1999-04-30 2003-11-18 Aclara Biosciences, Inc. Methods for detecting a plurality of analytes by mass spectrometry
US6162593A (en) * 1999-10-26 2000-12-19 Wyatt; Marion F. Diisopropylbenzene containing solvent and method of developing flexographic printing plates
DE19963849A1 (de) * 1999-12-30 2001-07-12 Giesecke & Devrient Gmbh Datenträger mit gedrucktem Sicherheitselement
US7306904B2 (en) * 2000-02-18 2007-12-11 Olink Ab Methods and kits for proximity probing
US6743911B2 (en) * 2000-03-14 2004-06-01 Shell Oil Company Process for the carbonylation of pentenenitrile
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
US7160735B2 (en) * 2000-04-28 2007-01-09 Monogram Biosciences, Inc. Tagged microparticle compositions and methods
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US7255999B2 (en) * 2001-05-21 2007-08-14 Monogram Biosciences, Inc. Methods and compositions for analyzing proteins
US20040067498A1 (en) * 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
US20030207300A1 (en) * 2000-04-28 2003-11-06 Matray Tracy J. Multiplex analytical platform using molecular tags
EP1309717A1 (en) * 2000-08-08 2003-05-14 Aclara BioSciences, Inc. Multiplexed enzymatic assays
ES2394293T3 (es) * 2001-02-28 2013-01-30 Bio Life Science Forschungs- Und Entwicklungsges.M.B.H. Vacuna contra cánceres que están asociados con el oncogén HER-2/neu
US7183388B2 (en) * 2001-03-30 2007-02-27 The Regents Of The University Of California Anti-MUC-1 single chain antibodies for tumor targeting
WO2002094998A2 (en) * 2001-05-21 2002-11-28 Aclara Biosciences, Inc. Analyzing phosphorylated proteins
US7358052B2 (en) * 2001-05-26 2008-04-15 Monogram Biosciences, Inc. Catalytic amplification of multiplexed assay signals
US7446185B2 (en) * 2001-07-18 2008-11-04 The Regents Of The University Of California Her2/neu target antigen and use of same to stimulate an immune response
US20040241688A1 (en) * 2001-07-19 2004-12-02 Cuneyt Bukusoglu Human tissue specific drug screening procedure
GB2378245A (en) * 2001-08-03 2003-02-05 Mats Nilsson Nucleic acid amplification method
WO2003033741A1 (en) * 2001-10-16 2003-04-24 Aclara Biosciences, Inc. Universal e-tag primer and probe compositions and methods
US7045311B2 (en) * 2001-10-25 2006-05-16 Monogram Biosciences, Inc. Whole cell assay systems for cell surface proteases
US6659577B2 (en) * 2001-12-06 2003-12-09 Hewlett-Packard Development Company, L.P. Dual flat springs for tool-less slide installation
US7135174B2 (en) * 2002-01-07 2006-11-14 Amgen Fremont, Inc. Antibodies directed to PDGFD and uses thereof
KR101048894B1 (ko) * 2002-02-26 2011-07-13 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 항-인간 테나신 단클론 항체
US6949347B2 (en) * 2002-03-05 2005-09-27 Aclara Biosciences, Inc. Multiplex analysis using membrane-bound sensitizers
WO2003085374A2 (en) * 2002-04-02 2003-10-16 Aclara Biosciences, Inc. Multiplexed assays using electrophoretically separated molecular tags
US7332580B2 (en) * 2002-04-05 2008-02-19 The Regents Of The University Of California Bispecific single chain Fv antibody molecules and methods of use thereof
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20040229293A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20090111127A1 (en) * 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US7402397B2 (en) * 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229299A1 (en) * 2002-05-21 2004-11-18 Badal M. Youssouf Intracellular complexes as biomarkers
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20040175765A1 (en) * 2002-07-05 2004-09-09 Sharat Singh Cell-screening assay and composition
PT2263691E (pt) * 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
CN1672054A (zh) * 2002-07-25 2005-09-21 阿克拉若生物科学公司 检测受体寡聚化
JP2006508907A (ja) * 2002-07-26 2006-03-16 アクララ バイオサイエンシーズ， インコーポレイテッド 親油性電気泳動プローブ
US20040091850A1 (en) * 2002-11-08 2004-05-13 Travis Boone Single cell analysis of membrane molecules
BRPI0408950A (pt) * 2003-04-01 2006-03-28 Monogram Biosciences Inc método para determinar a situação de doença de um paciente, e, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica
US20100291594A1 (en) * 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
US20060204966A1 (en) * 2003-08-01 2006-09-14 Spector Neil L Treatment of cancers expressing p95 erbb2
EP1673399B1 (en) * 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
EP1664716A4 (en) * 2003-08-15 2008-08-13 Smithkline Beecham Corp CANCER BIOMARKERS
US20050106571A1 (en) * 2003-10-02 2005-05-19 The Regents Of The University Of California Mammalian T1R3 sweet taste receptors
WO2005037071A2 (en) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
JP4011100B2 (ja) * 2004-07-09 2007-11-21 中外製薬株式会社 抗グリピカン３抗体
WO2006044748A2 (en) * 2004-10-15 2006-04-27 Monogram Biosciences, Inc. RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
WO2006137932A2 (en) * 2004-11-03 2006-12-28 Leucadia Technologies, Inc. Homogeneous analyte detection
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
US20060212956A1 (en) * 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2009070772A1 (en) * 2007-11-27 2009-06-04 Monogram Biosciences, Inc. Enhanced method for detecting and/or quantifying an analyte in a sample
US10416162B2 (en) * 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
ES2637411T3 (es) * 2008-12-01 2017-10-13 Laboratory Corporation Of America Holdings Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95
ES2535723T3 (es) * 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Métodos de determinación de la respuesta del paciente mediante la medición de Her-3

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1918386A9 (en) * 2002-03-13 2008-07-09 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
CN1928563A (zh) * 2005-09-09 2007-03-14 上海张江生物技术有限公司 乳腺癌的免疫组化诊断试剂盒和测试片
CN101230390A (zh) * 2007-12-07 2008-07-30 湖北大学 一种用于妇科恶性肿瘤早期筛选的基因芯片及其检测方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Correlation of ErbB activatiaon status and clinical response in Herceptin treated breast cancer patients.;Ali Mukherjee,et al.;《Proc Amer Assoc Cancer Res》;20050430;第46卷;摘要 *
HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements forconcomitant chemotherapy;BATES M P ET AL.;《JOURNAL OF CLINICAL ONCOLOGY》;20070620;第25卷(第18S期);1-3 *
Quantitative measurements of HER2 expression and HER2: HER2 dimerization identity subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment.;HUANG W ET AL.;《BREAST CANCER RESEARCH AND TREATMENT》;20071213;第106卷(第1期);S86 *

Also Published As

Publication number Publication date
WO2010083463A1 (en) 2010-07-22
EP2387717A4 (en) 2012-09-26
US20170082626A1 (en) 2017-03-23
JP2014074724A (ja) 2014-04-24
BRPI1007048A2 (pt) 2016-02-10
JP2012515353A (ja) 2012-07-05
US20100233732A1 (en) 2010-09-16
JP5615986B2 (ja) 2014-10-29
AU2010204576A1 (en) 2011-09-01
ES2526519T3 (es) 2015-01-13
EP2387717A1 (en) 2011-11-23
IL214067A0 (en) 2011-08-31
US20140370523A1 (en) 2014-12-18
WO2010083463A9 (en) 2010-12-23
CA2749817A1 (en) 2010-07-22
CN102439452A (zh) 2012-05-02
EP2387717B1 (en) 2014-12-10
SG172984A1 (en) 2011-08-29
KR20110120890A (ko) 2011-11-04

Similar Documents

Publication Publication Date Title
CN102439452B (zh) 通过测量her-2表达确定患者应答的方法
US10416162B2 (en) Her2 diagnostic methods
JP6402173B2 (ja) Ｈｅｒ３の検出に基づく癌の診断、予後予測、および処置を容易にするためのシステムおよび方法
KR20110120891A (ko) Ｈｅｒ-３의 측정에 의한 환자 반응의 결정 방법
US20130216523A1 (en) Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression
US11579148B2 (en) Methods for determining the likelihood of survival and for predicting likelihood of metastasis in cancer patients
US20230062274A1 (en) Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150415

Termination date: 20220115